Divi's Laboratories — Q3 FY26
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Capex for FY26 to exceed ₹2,000 crore
Management indicated that capex spend in H1 was ₹1,550 crore and full-year capex will be higher than the earlier guidance of ₹2,000 crore.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Constant currency revenue growth ~10-11% for FY26
Management expects constant currency growth for the full year to be similar to H1's 10.79%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Generic pricing pressure to persist for next 2 quarters
Management does not foresee improvement in generic pricing for at least the next two quarters.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1